ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

ClinicalTrials.gov ID: NCT06921759

Public ClinicalTrials.gov record NCT06921759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Study identification

NCT ID
NCT06921759
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
206 participants

Conditions and interventions

Interventions

  • Lebrikizumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 20, 2025
Primary completion
Apr 30, 2026
Completion
Jun 30, 2026
Last update posted
Apr 16, 2026

2025 – 2026

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
First OC Dermatology Research Inc Fountain Valley California 92708
Dermatology Research Associates Los Angeles California 90045
Encore Medical Research Hollywood Florida 33024
Research Associates of South Florida - Miami - Southwest 8th Street Miami Florida 33134
Renstar Medical Research Ocala Florida 34470
DeNova Research Chicago Illinois 60602
Southern Indiana Clinical Trials New Albany Indiana 47150
Revival Research Institute, LLC Troy Michigan 48084
MediSearch Clinical Trials Saint Joseph Missouri 64506
Care Access - Hoboken Hoboken New Jersey 07030
Optima Research - Boardman Boardman Ohio 44512
Progressive Clinical Research San Antonio Texas 78213
Texas Dermatology and Laser Specialists San Antonio Texas 78218
Complete Dermatology Sugar Land Texas 77479

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06921759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06921759 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →